Companies team up for needle-free botulinum injection platform
American Medical Systems (Minnetonka, MN) has signed a co-development agreement with Allergan, Inc. to jointly develop and seek regulatory approval for the delivery of onabotulinumtoxinA (Botox) using the AMS JetTouch system for treatment of overactive bladder.
American Medical Systems (Minnetonka, MN) has signed a co-development agreement with Allergan, Inc. to jointly develop and seek regulatory approval for the delivery of onabotulinumtoxinA (Botox) using the AMS JetTouch system for treatment of overactive bladder.
JetTouch is a novel injection platform that has the potential to enable needle-free injection into any area of the body reachable by endoscopic or percutaneous access, according to AMS. Needle-free injection with the JetTouch system is being evaluated as a means for local drug delivery and may provide treatment administration efficiencies for the physician.
Under the co-development agreement, AMS will first develop JetTouch for general use in the bladder. Subject to the FDA approval of onabotulinumtoxinA for injection by needle as a treatment for OAB, AMS, in collaboration with Allergan, will seek to add onabotulinumtoxinA to the JetTouch label, and Allergan plans to seek regulatory advice to add the delivery of onabotulinumtoxinA with JetTouch to the onabotulinumtoxinA label.
Go back to this issue of Urology Times eNews.
Related Content
Mid-urethral sling reduces incontinence after prolapse surgery
